About Us
Kalexo Bio is advancing dual-targeting siRNA therapeutics to address the most critical unmet needs in cardiovascular disease. By dual-targeting the key genetic drivers of cardiovascular disease, our approach is designed to deliver potent, durable risk reduction—starting with lipid management and atherosclerotic disease prevention. Our lead program has the potential to redefine the standard of care.
Backed by a deeply experienced team, we are committed to transforming outcomes for patients and creating meaningful value within the cardiovascular field.
Transforming Cardiovascular Disease with Next-Generation siRNA Therapeutics
Our Approach
Targeting the Genetic Drivers of Cardiovascular Disease
Kalexo Bio is focused on addressing the significant unmet need in cardiovascular disease by targeting genetically validated drivers with durable siRNA therapeutics.
Our lead program targets the most impactful risk factors to enable deeper, more sustained cardiovascular risk reduction and prevent atherosclerotic events.
Dual Target Therapy for Multiple Indications
Our dual-target siRNA approach is designed to maximize cardiovascular risk reduction by simultaneously addressing two key drivers of residual risk despite statin therapy. Our lead candidate, KLX-1101, is an advanced divalent siRNA engineered to silence these targets in a single regimen, with the potential to redefine lipid management and prevent ASCVD (atherosclerotic cardiovascular disease) events.
In preclinical studies, KLX-1101 has demonstrated strong target suppression with minimal off-target effects.
Our Focus
Tackling the Growing Burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the leading cause of death worldwide, driven in large part by elevated lipids. Elevated lipids are significant contributors to atherosclerosis, increases the risk of heart attack, stroke, and cardiovascular death. Despite available therapies, these drivers continue to fuel a substantial global disease burden.
1
Despite advances in lipid-lowering therapies, many patients remain at high risk for major ASCVD events, underscoring a critical gap in care. Kalexo Bio is addressing this unmet need by advancing siRNA therapeutics that target the genetic drivers of cardiovascular disease to deliver deeper, more durable risk reduction and change the trajectory of cardiovascular care.
The Urgent Need for Next-Generation Lipid Solutions
Reference:
1 World Health Organization, www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Leadership and Team
Praveena Kandula, MD
President
Suzy Benedict
Senior Vice President, Regulatory Affairs
Simon Wong, PhD
VP, Nonclinical Development and Clinical Pharmacology
Ella Kleynerman
Senior Director of Clinical Operations
Robert Schott, MD, MPH, FACC
Chief Medical Officer
Shyanne Ali
Senior Vice President, Quality
Mike Holfinger, PhD
Senior Vice President, CMC
Karson Kump
Senior Director, Buisness Development
Srini Ramanathan, PhD
Chief Development Officer
Vicki Sung, PhD
Senior Vice President, Nonclinical Development
Julie Shah
Vice President,
Head of Legal
Chamara Jayesinghe
Senior Director, Program Management
Chris Daige
Vice President, Toxicology
Liang Chang, PhD
Senior Associate
Board and Advisors
Joe Jiminez
Board Director
Praveena Kandula, MD
President & Board Director
Mark Fishman, MD
Chair of the Scientific Advisory Board, Aditum Bio
Josh Gertsman
Board Director